{
    "url_original": "https://www.wsj.com/articles/johnson-johnson-posts-higher-quarterly-profit-as-healthcare-demand-returns-11626867300?mod=business_lead_pos1",
    "url": "johnson-johnson-posts-higher-quarterly-profit-as-healthcare-demand-returns-11626867300",
    "title": "Johnson & Johnson Posts Higher Profit as Healthcare Demand Returns",
    "sub_head": "Company raises guidance for rest of the year as Covid-19 vaccination campaign continues",
    "category_1": "Business",
    "category_2": "Earnings",
    "image_1_url": "https://images.wsj.net/im-372385?width=860&height=573",
    "image_1": "im-372385.jpg",
    "time": "2021-07-21 07:35:00",
    "body": "Greater demand for medical devices, drugs and consumer-health products helped boost sales and profit for  Johnson & Johnson  in the latest quarter, as the company’s Covid-19 shot continued to play a role in vaccination campaigns.<br />As people returned for healthcare they had deferred earlier in the coronavirus pandemic, sales of J&J’s medical devices climbed 63% year over year. Higher sales of the company’s skin care and beauty products helped lift J&J’s consumer-health revenue by 13% compared with a year earlier.<br />J&J’s Covid-19 vaccine contributed revenue of $165 million between April and June, a rise from $100 million in the first three months of the year.<br />Pharmaceutical sales rose 17% overall, driven by higher sales of Stelara, a drug for inflammatory diseases, Darzalex, a multiple-myeloma drug, and Tremfya, a drug for plaque psoriasis and psoriatic arthritis.<br />The New Brunswick, N.J.-based company logged sales of $23.31 billion—a 27% increase year over year—and adjusted earnings of $2.48 a share. Wall Street analysts had forecast adjusted earnings of $2.29 a share and revenue of $22.49 billion, according to FactSet’s survey."
}